The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).

Start Date25 May 2018

Sponsor / Collaborator

Allergan Ltd. (Ireland)

NCT03335852 / CompletedPhase 1

Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)

This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese patients with neovascular age-related macular degeneration (AMD).

Start Date28 Nov 2017

Sponsor / Collaborator

Allergan Ltd. (Ireland)

NCT02859766 / CompletedPhase 1

Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol in treatment-naïve patients with neovascular age-related macular degeneration (AMD).

Start Date07 Dec 2016

Sponsor / Collaborator

Allergan Ltd. (Ireland)

100 Clinical Results associated with Abicipar pegol

100 Translational Medicine associated with Abicipar pegol

100 Patents (Medical) associated with Abicipar pegol

Literatures (Medical) associated with Abicipar pegol

02 Oct 2024·Expert Opinion on Drug Metabolism & Toxicology

Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability

Review

Author: Stewart, Michael W.

INTRODUCTION:

The modern treatment of chorioretinal vascular diseases follows the recent development and rapid adoption of drugs that inhibit vascular endothelial growth factor (VEGF). All anti-VEGF drugs are delivered intravitreally, with clinical behavior, including efficacy, durability, and safety, largely determined by their pharmacokinetic properties.

AREAS COVERED:

Properties of these new drugs include additional binding targets (placental growth factor (PlGF) and angiopoietin 2 (Ang 2)), binding affinity, potency, intravitreal half-life, and increased molar dose. A PubMed search for 'pharmacokinetics of anti-VEGF drugs' was performed from 2000 to 2023. Relevant studies were reviewed and referred to in the manuscript.

EXPERT OPINION:

Early developers concentrated on improving efficacy, but since maximum efficacy with VEGF inhibition has been reached, development has pivoted to extending the duration of action. Durability strategies include inhibiting additional pathways (faricimab), increasing molar dose (abicipar, brolucizumab, faricimab, and aflibercept 8 mg), and prolonging the intravitreal half-life (abicipar and KSI-301). Recent phase 3 trials demonstrated modest improvements in durability, but failures that might be attributed to these strategies (conjugation and manufacturing processes) have occurred. Future drug development focuses on extending duration of action with implantable reservoirs (ranibizumab port delivery system), sustained release devices (tyrosine kinase inhibitors), and gene therapy.

01 Jul 2023·Archivos de la Sociedad Espanola de Oftalmologia

Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious

Review

Author: Gallego-Pinazo, R ; Dolz-Marco, R ; Montolío-Marzo, E ; Vidal-Oliver, L ; Montolío-Marzo, S

The recent release of brolucizumab and the development of new antiangiogenic molecules as abicipar pegol has increased the interest towards inflammatory complications after intravitreal drug injection. Those drugs are associated to a higher rate of inflammatory adverse events compared to classic drugs. In this context it is essential to differentiate between sterile and infectious cases for a fast and effective treatment. The clinical similarities between infectious and sterile cases, the high rate of culture negative patients and the heterogeneity in the terminology used are obstacles for a correct diagnosis and report of these complications. Sterile cases appear early after the injection, before 48 h; or 20 days after in brolucizumab-related vasculitis cases. Infectious cases show up around the third day after injection and up to a week after it. A severe visual impairment, severe pain, severe hyperemia, hypopyon and a more severe intraocular inflammatory process are signs of a likely infectious origin. If the cause of the inflammation is uncertain we must follow up the patient closely or "tap and inject" antimicrobial agents in order to prevent the eventual complications of an infectious endophthalmitis. On the other hand, sterile endophthalmitis might be observed in mild cases or treated with steroids according to the severity of the inflammation.

01 Jan 2023·Vestnik oftalmologii

[Modern trends in anti-VEGF therapy for age-related macular degeneration].

Article

Author: Alkharki, L ; Budzinskaya, M V ; Plyukhova, A A

Age-related macular degeneration (AMD) develops in people aged 50 years and older, its pathogenesis involves progressive destruction of the retinal pigment epithelium and Bruch's membrane. There are eight currently known anti-VEGF drugs for treating the neovascular form of AMD, four of them have already been registered and are used in clinical practice. The first registered drug was pegaptanib, which selectively blocks VEGF₁₆₅. Subsequently, a molecule with a similar mechanism of action was developed and named ranibizumab, which is a humanized monoclonal Fab fragment; it was specifically designed for ophthalmology. Its advantage over pegaptanib was neutralization of all active VEGF-A isoforms. Aflibercept and conbercept are recombinant fusion proteins that act as soluble decoy receptors for VEGF family proteins. Phase III data from the VIEW 1 and 2 studies showed that intraocular injections (IVI) of aflibercept every 1 or 2 months for a year resulted in comparable functional outcomes to monthly IVI of ranibizumab for one year. The next molecule for anti-VEGF therapy that showed effectiveness was brolucizumab - a single-chain fragment of a humanized antibody that binds with high affinity to various VEGF-A isoforms. Simultaneously with studying brolucizumab, another study was conducted involving Abicipar pegol, but that drug showed a high rate of complications. The latest drug registered for the treatment of neovascular AMD is faricimab. The molecule of this drug is a humanized immunoglobulin G antibody that acts on two key points of angiogenesis: VEGF-A and angiopoietin-2 (Ang-2). Thus, the strategy for advancing anti-VEGF therapy lies in the development of molecules with greater efficiency (better effect on newly formed vessels leading to resorption of exudate in the retina, under the neuroepithelium and under the retinal pigment epithelium), which allows not just to preserve vision, but to also significantly improve it when there is no macular atrophy.

News (Medical) associated with Abicipar pegol

27 May 2023

·pipelinereview.com

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination studies with potential partners ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I May 25, 2023 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from the ongoing Phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) Annual Meeting, held June 2–6 in Chicago, Illinois. The data demonstrate that MP0317 shows evidence of tumor-localized CD40 activation (analyses in paired tumor biopsies). The detection of MP0317 in tumors positively correlated with immune activation when comparing high vs. low doses of MP0317. This detection was associated with a statistically significant CD40-mediated increase of antigen-presenting cells and interferon γ signature. Furthermore, MP0317 has demonstrated a favorable safety profile. The current data support planning of future combination studies. “These positive data continue to demonstrate that MP0317’s unique mechanism of action has the potential to overcome the limitations of existing therapies that target CD40 by activating only in the tumor microenvironment and therefore avoid systemic toxicities seen by other treatments,” said Nicolas Leupin, MD, Ph.D., Chief Medical Officer of Molecular Partners. “MP0317 encapsulates the advantages we believe we can achieve through our DARPin platform: to design candidates to overcome biological challenges that other drug classes like antibodies cannot address. These data of the ongoing study will further support the advancement of MP0317 into later-stage clinical research with partners and highlight the potential of MP0317 for evaluation in combination settings.” “Clinical data from 36 patients with advanced solid tumors, dosed across 8 dose levels, confirms that the tumor-FAP-targeted CD40 agonist MP0317 is safe and well tolerated with limited systemic inflammation compared to other CD40 agonists,” said Dr Carlos Gomez-Roca, Head of the Early Phase & Clinical Research Unit at IUCT-Oncopole Claudius Regaud at Toulouse, France, and investigator on the study. “The analysis of paired pre- and on treatment tumor biopsies as well as peripheral biomarkers provides evidence of target occupancy and pharmacodynamic modulation in the tumor microenvironment, consistent with tumor localised CD40 activation. The current data enables further evaluation of MP0317 in combination.” This ongoing first-in-human Phase 1, open-label, dose-escalation study assesses the safety and tolerability as well as pharmacokinetics/pharmacodynamics and antitumor activity of MP0317 monotherapy in patients with refractory/relapsed solid tumors known to express FAP and CD40 (NCT05098405 ) . To date, the 36 patients enrolled in the Netherlands and France across eight dosing cohorts received MP0317 at doses of 0.03–10 mg/kg in every-3-weeks [q3w] and weekly [q1w] schedules (data cut-off 02 May 2023). MP0317 monotherapy was seen to result in tumor-localized CD40 activation: biomarker data confirmed presence of MP0317 in the tumors of patients with evaluable pre- and on-treatment biopsies as of the cutoff date. This detection of MP0317 in tumors positively correlates when comparing high vs. low doses of MP0317 and was associated with a statistically significant CD40-mediated increase of antigen-presenting cells as well as interferon γ production within the tumor microenvironment. To date, one patient achieved an unconfirmed partial response and stable disease was observed in 5 additional patients. The observed safety profile of MP0317 monotherapy to date is favorable. A dose-limiting toxicity was reported in one patient (transient asymptomatic Grade 3 elevation of liver enzymes), at the highest planned MP0317 dose of 10 mg/kg administered q3w. The positive results of this ongoing Phase 1 study in patients with refractory/relapsed tumors support continued clinical evaluation of MP0317 and potential investigation in combination studies. The study continues to enroll one more cohort (q1w). For further information please see clinicaltrials.gov (NCT05098405). The details of the poster presenting these results from the ongoing Phase 1 study at the ASCO 2023 Annual Meeting can be found below. The poster will be made available on Molecular Partners' website after the presentation. Title: Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors Poster Session: Developmental Therapeutics—Immunotherapy Abstract number: 2584 Poster number: 426 Location & Timing: Hall A; June 3, 2023; 8:00–11:00am CDT Authors & Affiliations: C Gomez-Roca 1 , N Steeghs 2 , E Gort 3 , H De Winter 4 , E Fernandez 4 , V Stavropoulou 4 , N Stojcheva 4 , P Baverel 4 , J Krieg 4 , K Ioannou 4 , A Florescu 4 , P Mossi 4 , L Hoenig 4 , B Baud-Berthier 4 , V Kirkin 4 , A Goubier 4 , P Legenne 4 , P Cassier 5 About MP0317 MP0317 targets both the FAP and the immunostimulatory protein CD40 to enable tumor-localized immune activation. Through this proposed mechanism of action, MP0317 is designed to activate immune cells specifically within the tumor microenvironment, potentially delivering greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com ; Find us on Twitter - @MolecularPrtnrs 1 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France 2 The Netherlands Cancer Institute, Amsterdam, the Netherlands 3 UMC Utrecht, Utrecht, the Netherlands 4 Molecular Partners AG, Schlieren-Zurich, Switzerland; 5 Centre Léon Bérard, Lyon, France SOURCE: Molecular Partners

Phase 1ASCOClinical ResultImmunotherapy

11 Jan 2023

·www.fiercebiotech.com

JPM23, Day 3: Ionis CEO concedes PCSK9 ship may have sailed; Nektar forges ahead after bempeg blowup

While M&A deals may have dried up on Day 2, we're still holding out hope for a JPM-defining blockbuster acquisition. We're off for another day of the J.P. Morgan Healthcare Conference. The flood of licensing agreements may have slowed, but there's still plenty of action to come as companies make pitches to their peers, investors and industry watchers. Some notable highlights from yesterday included Sage Therapeutics setting out its stall for depression drug zuranolone, while Karuna Therapeutics suggested that it didn’t need to take advantage of swirling acquisition rumors to scale up its hotly anticipated schizophrenia drug. And while M&A deals may have dried up on Day 2, we're still holding out hope for a JPM-defining blockbuster acquisition. If that happens, you'll hear about it right here. Our Day 1 conference tracker is available here, and all the Day 2 action is wrapped here. Fierce Pharma’s take on the action so far can be found here and here. 6:05 p.m. ET: It appears that Ionis’ PCSK9 hopes are dimming. CEO Brett Monia told Fierce Biotech in an exclusive interview that the recently returned drug does not fit the company’s plans. The med, ION449, was returned to Ionis from AstraZeneca following a phase 2 data readout last year. The prospects of the company’s factor XI med, fesomersen, are more promising, however. Story 1:08 p.m. ET: Annexon Biosciences CEO Douglas Love said the company is giving itself "two ways to win” in the upcoming pivotal phase 2/3 trial for Huntington’s disease therapy ANX005, during his remarks at the JPM Wednesday morning. Love previewed the year ahead, which includes initiating ANX1502 in phase 1 studies for autoimmune indications, completing phase 3 enrollment for ANX005 in Guillain-Barre syndrome (GBS) and initiating the phase 2/3 trial for Huntington’s disease. Story 12:50 p.m. ET: Nektar Therapeutics is forging ahead with its existing pipeline, months after the failure of bempeg crumbled a multi-billion dollar deal with Bristol Myers Squibb. The company’s comeback story hinges mainly on two clinical-stage assets, one of which is a part of a collaboration with Lilly. A readout for that drug, rezpeg, is expected from a phase 2 trial in patients with lupus within the first half of the year, with CEO Howard Robin saying at the J.P. Morgan Healthcare Conference that he hopes the data is ready “sooner rather than later.” Nektar’s remaining cancer opportunity rests solely on NKTR-255, an IL-15 agonist being teed up as a combo med for a number of cancer treatments. Story 12:05 p.m. ET: Novartis’ deal with Molecular Partners at the end of 2021 not only secured the biotech a potential $560 million biobucks payday in the future, it also cemented the reputation of radioligands as a “truly hot” therapy area for investors. At least, that’s how Molecular Partners CEO Patrick Amstutz, Ph.D., tells it. “It’s hot because companies like Novartis have presented data, especially in prostate [cancer],” Amstutz told a JPM session. “So amazing results, and really opening this field for additional treatment.” With radioligand programs progressing, as well as moving its first T cell engager into the clinic “literally any day” now, it’s a good thing the biotech has plenty of cash in the bank. “We’re well capitalized until 2026, not something we should take for granted in these stormy conditions,” the CEO said. One outlier is Abicipar, a late-stage eye drug that was initially licensed out to Allergan and ultimately returned to Molecular Partners a decade later. The Swiss biotech is still on the lookout for a suitable partner, said Amstutz, who claimed the drug produced “beautiful data” in a late-stage trial for wet age-related macular degeneration. FDA concerns around inflammation put the breaks on approval hopes, but the CEO said the company has since had a “breakthrough” that the inflammation was caused by the type of syringe used. “It seems we have solved the problem to have less inflammation,” Amstutz said. “We will not pursue this in Molecular Partners but we are in discussions to see if there is a path forward with this drug, especially as it would only need one additional safety trial to get it approved.” While the conference is notorious for its dealmaking and partnership announcements, Takeda’s head of GI therapeutics Chinwe Ukomadu, M.D., Ph.D., told Fierce Biotech on the sidelines that the Japanese pharma is always looking for potential collaborators. “We don’t wait for JPM,” Ukomadu said. “We’re having conversations all along with the companies. We see them on our team meetings, Zoom meetings, but there’s something unique about getting to sit with them in person now.” The moral of the story? To be successful, Big Pharmas can’t be too inward looking. Under the guidance of R&D head Andy Plump, M.D., Ph.D., Takeda has built out 90% of its pipeline assets in fewer than 10 years, a feat only possible via collaboration.

Phase 2AcquisitionPhase 3

09 Aug 2021

·endpts.com

AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?

One of the programs that headlined AbbVie’s $63 billion acquisition of Allergan is being returned to its developers after an FDA rejection last year. AbbVie has terminated the license and collaboration agreement it had with Switzerland’s Molecular Partners for abicipar, the companies announced Monday, an experimental drug aimed to treat neovascular age-related macular degeneration and diabetic macular edema. Abicipar was rejected by the FDA in June 2020 due to what AbbVie said was an unfavorable benefit-risk ratio, according to its description of the CRL. Molecular Partners’ stock $MOLN was down about 4% on the Swiss stock exchange in the wake of Monday’s news. In order to determine next steps for the program, Molecular Partners said in a release that it will establish a “special committee.” Company spokesperson Seth Lewis told Endpoints News in an interview that the committee will likely be composed primarily of internal staffers but may bring on outside expertise “as needed.” Lewis further emphasized that future plans are still in the nascent stage, given that Molecular Partners only received notification of the termination Monday. The company has yet to receive all the materials associated with the program, with Lewis saying Allergan had essentially owned the program outright and made all major decisions. While Molecular Partners had been kept informed of the program’s progress, Lewis attempted to distance the biotech from Allergan, saying the relationship between the companies has “ebbed and flowed” in the years since licensing abicipar back in 2011. Lewis stressed that since that time, Molecular Partners had built out a portfolio largely unrelated to ophthalmology. Other programs are not expected to be affected by the termination, as the release noted that the companies will continue partnering on ophthalmic indications. Abicipar had been expected to play a big part in the famed Allergan buyout and challenge the Roche drug Lucentis and the Regeneron giant Eylea, with former Allergan CEO Brent Saunders saying back in May 2019 the program was one of four “expected” to gain FDA approval. The candidate had passed two Phase III tests a year earlier, as Allergan touted both eight- and 12-week regimens. But those studies also flagged that the incidence of intraocular inflammation proved higher in patients on abicipar than those on Lucentis, which regulators took issue with in the CRL, Lewis said. Allergan had conducted a separate open-label, single-arm study around the same time as the Phase III trials, showing new manufacturing processes appeared to have led to a lower rate of inflammation. That study was not included in the pivotal program, however. The intraocular inflammation rate in this trial was 8.9%, or around numerically half the rate observed in prior Phase III studies, which hovered around 15%. Lewis said the threshold the FDA is looking for is around 5%, and another pivotal study looking at further lowered rates could be in the cards. “If you think about the history of Allergan, they were a great commercial company when we did the deal with them back in 2011, and it was very exciting to be able to do that, but their knowledge of biological manufacturing wasn’t that great at the time,” Lewis told Endpoints. “The knowledge and increased efficacy of process that’s been built up over that time should allow for continued improvements.”

Acquisition

100 Deals associated with Abicipar pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D11517	-	-	DB12258

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet Macular Degeneration	NDA/BLA	EU	-	-
Age Related Macular Degeneration	Phase 3	US	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	JP	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AR	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AU	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AT	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	BR	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CA	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CL	Allergan Ltd. (Ireland)	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CO	Allergan Ltd. (Ireland)	25 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03539549 (CTgov)	Phase 2	Wet age-related macular degeneration	124	Abicipar pegol	gtnbpqxrep(tsexorpwhu) = djrtjdxpij gowolieekb (kkshwoinhv, mcjserbnnd - yonaxvkloz) View more	-	03 Aug 2020
NCT02462486 (SEQUOIA, CTgov)	Phase 3	Age Related Macular Degeneration	949	Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q8))	mdjwjtbupx(eznmlmiztw) = tbbbxqrznm txsrtxjxbm (jccuoqblue, zjthnzpskd - pjthqoolbp) View more	-	30 Jul 2020
				Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q12))	mdjwjtbupx(eznmlmiztw) = sgwrvzumks txsrtxjxbm (jccuoqblue, jkkkhvfviw - lwalicudbn) View more
NCT02462928 (CEDAR, CTgov)	Phase 3	Age Related Macular Degeneration	939	Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q8))	sztteefroi(ibdcvdamuy) = ovynmlektx dtayywzuwu (lxprtaanqm, ewwmjadito - ywftlxmjau) View more	-	28 Jul 2020
				Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q12))	sztteefroi(ibdcvdamuy) = svpujmbzqf dtayywzuwu (lxprtaanqm, zqgcaznfhk - vbhnuvhosv) View more
NCT02462486 \| NCT02462928 (CEDAR, ARVO2019)	Phase 3	Wet age-related macular degeneration	-	abicipar 2q8	xwogpkizmv(heohtafird) = oooipberpy bdpnbflhxt (rpzpqmsnng )	Positive	01 Jul 2019
				abicipar 2q12	xwogpkizmv(heohtafird) = ktxmziuubr bdpnbflhxt (rpzpqmsnng )
NCT02181504 (CTgov)	Phase 2	Wet age-related macular degeneration	25	sham procedure+abicipar pegol (Abicipar Pegol 2 mg)	ixsvjsiixv(dsxiiipgji) = itdqhqxadj vhkapepmgr (pvvsopkcef, hccugtelmc - hxyvubzvfi) View more	-	25 Apr 2017
				sham procedure+abicipar pegol (Abicipar Pegol 1 mg)	ixsvjsiixv(dsxiiipgji) = hddhtthyzj vhkapepmgr (pvvsopkcef, ydbwrzrcmm - scttbvekzy) View more
NCT02181517 (CTgov)	Phase 2	Wet age-related macular degeneration	25	sham procedure+abicipar pegol (Abicipar Pegol 1 mg)	ijzvppxswd(ewlhgdwigs) = bmtcqdzifu taczkesnrf (jpkxydzuul, ufwiwohwlt - rrztclkbyt) View more	-	05 Apr 2016
				sham procedure+abicipar pegol (Abicipar Pegol 2 mg)	ijzvppxswd(ewlhgdwigs) = ngtvaqjxns taczkesnrf (jpkxydzuul, wkvsjpkysu - tqnrunyghr) View more
NCT01086761 (Pubmed \| Am J Ophthalmol)	Phase 1/2	Wet age-related macular degeneration	32	MP0112 1.0 or 2.0 mg	(hgldadanxd) = because of a case of endophthalmitis in the 2.0 mg cohort xsoorukaeo (nlfoednhae ) View more	-	01 Oct 2014
NCT01042678 (CTgov)	Phase 1	Diabetic macular oedema	18	MP0112 (MP0112 (0.04 mg))	xvukqwxclj(ttcxegcrzn) = tkamwclkdk svixvzaalk (euqlmsnmja, chaxpwbmdo - tcocdjdppf) View more	-	13 May 2014
				MP0112 (MP0112 (0.15 mg))	xvukqwxclj(ttcxegcrzn) = ebgvswsvxb svixvzaalk (euqlmsnmja, qxfzlzzslp - ekpohyngxg) View more
NCT01086761 (Phase I MP0112 Wet AMD Study, CTgov)	Phase 1	Wet age-related macular degeneration	32	MP0112 (MP0112 (0.04 mg))	oamhxyjijk(tekoiqadyh) = wgicoatamg nevmnrbdpe (xkxpbqojmr, alqqeqkzfl - stqoosjrmu) View more	-	12 May 2014
				MP0112 (MP0112 (0.15 mg))	oamhxyjijk(tekoiqadyh) = wlmbvektcg nevmnrbdpe (xkxpbqojmr, pcuyqobpnr - grvuacabbp) View more
NCT01042678 (ARVO2011)	Phase 1/2	Diabetic macular oedema	-	DARPin® MP0112	ehzbkiemrq(fdijuhzfdq) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences djrzrdcmzz (yrfusjdsmb )	-	01 Apr 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis